HBOT Conversations:
Dr. Paul Harch & Inflammation
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Inflammation is the first in a 9 episode series that will be released weekly with Dr. Harch.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with special guest and HBOT expert, Dr. Paul G. Harch, MD. This is the first of nine episodes with Dr. Harch examining the God-given miracle of Hyperbaric Oxygen Therapy.
In this episode, we dive into how HBOT is a game-changer for inflammation. Harch explains that inflammation is the driving factor for countless chronic illnesses, but thankfully Hyperbaric Oxygen Therapy is a natural proven way to suppress inflammation.
Harch summarizes a fascinating study done in 2008, by Dr. Cassandra Godman. Her team took skin biopsies and extracted the normal tissue, then they examined the cells that lined the tiniest blood vessels in the tissue. Next, they put these cells in a petri dish and put them in a hyperbaric chamber and gave him a single hyperbaric treatment. Afterwards, they did a mass gene array analysis for 48 hours. What happened next was ground-breaking in better understanding the role that HBOT has on inflammation.
At the end of 24 hours 8,101 of our 19,000 protein coding genes in our 23 chromosomes were either significantly turned on or turned off & suppressed. That single HBOT treatment turned on the anti-inflammatory genes and the growth and repair hormone genes, and the largest cluster suppressed were the pro-inflammatory genes.
Our inflammatory reaction is inescapable when an injury occurs. But, when the patient receives hyperbaric oxygen therapy treatment after an injury (the sooner the better), it can have an overwhelming positive influence on the inflammatory reaction at any place along the spectrum. Harch continues to explain that the anti-inflammatory effects of hyperbaric oxygen are wide-ranging.
Harch spoke of the Navy’s experience with Hyperbaric Oxygen Therapy, as the Navy really kind of dominated this field for many years. The Navy reported that if you can get someone in a chamber within one hour of coming out of the water – when they’re symptomatic for decompression sickness – then the first hyperbaric treatment is curative in 90% of cases. Everyone thought that HBOT was treating bubbles in the brain at that point, but the reality is they were treating inflammation. We now know that it’s the inflammatory reaction in the brain after the bubbles passed that Hyperbaric Oxygen Therapy is treating; not the bubbles.
HBOT isn’t new, it dates back well over a hundred years. It’s still misunderstood, because many believe that HBOT therapy is a treatment for diseases. But, the reality is that HBOT is a treatment for disease processes, and it’s these processes that cause the diseases. We treat the inflammation that causes the disease processes, and in turn we treat the disease. That’s the power of Hyperbaric Oxygen Therapy.
Stay tuned for all nine episodes that will be release each Friday for the next eight weeks.
Guest

Dr. Paul G. Harch, MD
Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – Intrathecal Magnesium for Same-day-surgery
5% hyperbaric lidocaine has lost its usefulness for same-day-surgery (SDS) anaesthesia
because it has been blamed responsible for the so-called transitory neurological syndrome
(TNS). This entity appears particularly in patients operated on lithotomy and knee
arthroscopy position and obese patients. It is a benign, moderately painful (grade 3-4 out of
10) and self-limited in time, but disturbing enough to be avoided in same-day-surgery cases.
Other local anesthetics are not competitive with general anesthesia in time to be discharged
home from the SDS unit. The magnesium ion is well-known for its protective properties on
cells with electrical activity. The objective is to confirm that the magnesium ion added as
adjuvant to intrathecal (IT) lidocaine may antagonize TNS incidence. If this hypothesis could
be confirmed, the practical and theoretical consequences would be far-reaching.
The method to achieve our objective would be a double-blinded randomized clinical trial
considering two groups of intrathecal lidocaine: with and without added IT magnesium.
Clinical Trial – Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture
There is a elevated risk of acute compartment syndrome (ACS) related to tibial shaft
fractures due to oedema and reduced blood flow in traumatised tissues. This may lead to lack
of oxygen and even necrosis. Symptoms of ACS are severe pain, hypoaesthesia, pain during
flexion of the ankle and swollen leg in clinical examination. Paralysis and lack of distal
pulses are late symptoms of ACS.
Many experts think that effective relief of pain caused by regional anaesthesia (RA) may hide
the symptoms of the ACS. This may be incorrect. The evidence of dangers related to RA is
based on old patient-series and single case-reports. Some of these studies report the
symptoms of ACS (hypaesthesia and even pain) being caused by RA. Majority of the conclusions
in these studies cannot be confirmed by an expert of RA. It is also possible that there are
more hemodynamic changes related to general anaesthesia (GA) which may predispose to ACS.
There are no modern, randomized and controlled studies of the safety of RA in patients with
tibial shaft fracture.
Late rectal and bladder toxicity following radiation therapy for prostate cancer: Predictive factors and treatment results.
Abstract: This study aimed at investigating factors associated to late rectal and bladder toxicity following radiation therapy and the effectiveness of Hyperbaric Oxygen Therapy (HBOT) when toxicity is grade ≥2. Radiation is frequently used for prostate cancer, but a...
